Back to search

University of Thessaly (UTH)

Κλινική εφαρμογή των φαρμακογενετικών ελέγχων στη θεραπευτική των νεοπλασιών

Abstract

dc:description

Pharmacogenomics is the study of the role of the heredity in the variance of patient response to treatment. While genetic studies have reveal millions of potential prognostic markers, a very small percentage of these indicators is expected to provide clinically useful information. The identification of genetic markers that predict response to therapy (predictors) is the first step towards the translation of Pharmacogenomics into clinical practice. The transition from research to clinical practice is expected to be time-consuming, laborious and costly. Thus, systematic collection, synthesis and evaluation of available pharmacogenomic data are required in order the scientific community to determine for their usefulness. The synthesis of the results of these studies can be done with meta-analytisis techniques. The aim of this thesis was to search for genetic markers that can impact on response to treatments in hematological malignancies ([Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML)] with the systematic collection, synthesis and meta-analysis as well as the quality evaluation of the available pharmacogenomic data. A systematic literature search per disease, was conducted, followed by extraction of the relevant data from these studies, synthesis of results with statistical methods and assessment of methodological quality of the studies. In CLL, systematic search of published pharmacogenomic studies that investigated genetic markers and response to treatment was conducted. A total of 13 indicators were studied. From the meta-analysis that carried out, it was shown that the mutation status in genes of variant region of heavy chain of immunoglobulin (IGVH) of clonal cells is associated with the response to treatment. Patients that exhibit mutations have two times more probability to respond to treatment. On the contrary, it seemed that the presence of mutations in genes TP53 and ATM is associated with poor response to treatment, as well as the presence of cytogenetic abnormalities del17p and del11q as well as trisomy 12. Moreover, overexpression of CD38 was associated with poor response to treatment. In MDS, similarly, a systematic search of published pharmacogenomic studies investigating genetic markers and response to treatment was conducted. Overall 23 genetic markers were meta-analysed. The results have shown that there is no significant correlation between any genetic marker with response to treatment. In AML the polymorphisms of the gene MDR 1 (Multi-Drug Resistance-1 gene) as well as the level of mRNA expression were studied since MDR1 is considered a major cause of multiple pharmaceutical resistance (multi drug resistance) and it is implicated in the response to chemotherapy of patients with AML. The meta-analysis revealed that the overexpression of mRNA is associated with poor response to treatment, while the polymorphisms that studied did not significantly correlate with response to treatment. In conclusion, the findings of this thesis resulted from the composition of pharmacogenomic studies with modern statistical techniques can assist in the improvement of the research on the identification of genetic markers that predict response to therapy and their transition into clinical practice at the studied hematological malignancies.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Doxani, Chrysoula
  • Δοξάνη, Χρυσούλα

Subjects

dc:subject × 24

Rights

dc:rights
Statement dc:rights
  • BY
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38567

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Doxani, Chrysoula; Δοξάνη, Χρυσούλα. Κλινική εφαρμογή των φαρμακογενετικών ελέγχων στη θεραπευτική των νεοπλασιών. University of Thessaly (UTH), 2016. http://hdl.handle.net/10442/hedi/38567